St. Jude partners with nation’s top cancer centers to endorse goal of eliminating HPV-related cancers in the United States
Joint statement empowers parents, young adults and physicians to act to increase vaccination rates and screenings to eliminate HPV-related cancers
Study found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and led to more complications.
St. Jude experts share pediatric oncology and survivorship research at the annual meeting of the American Society of Clinical Oncology.
Read about the algorithm that helped researchers uncover hidden drivers of immune regulation and production of anti-tumor T cells.
Hospital invests more than $100 million to improve childhood cancer survival rates worldwide.
For a subset of the youngest patients with the brain tumor medulloblastoma, less aggressive therapy was associated with better long-term survival.
The protein called BOK offers another target for drugs to selectively trigger apoptosis.
St. Jude is partnering with WHO to develop strategies that strengthen the global resources, organization and planning needed to identify and treat pediatric cancer.
Researchers created the first genetic screening guidelines for medulloblastoma patients after identifying gene variations that make carriers susceptible.
Using combination therapy for flu, a new class of drug offers potential for multi-drug therapy and possibly improved influenza-fighting drugs.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.